DE60021570D1 - Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor - Google Patents

Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor

Info

Publication number
DE60021570D1
DE60021570D1 DE60021570T DE60021570T DE60021570D1 DE 60021570 D1 DE60021570 D1 DE 60021570D1 DE 60021570 T DE60021570 T DE 60021570T DE 60021570 T DE60021570 T DE 60021570T DE 60021570 D1 DE60021570 D1 DE 60021570D1
Authority
DE
Germany
Prior art keywords
acid
elastile
proton pump
pump inhibitor
pharmaceutical form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60021570T
Other languages
English (en)
Other versions
DE60021570T2 (de
Inventor
Rango Dietrich
Rudolf Linder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Altana Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma AG filed Critical Altana Pharma AG
Publication of DE60021570D1 publication Critical patent/DE60021570D1/de
Application granted granted Critical
Publication of DE60021570T2 publication Critical patent/DE60021570T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60021570T 1999-06-07 2000-05-31 Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor Expired - Lifetime DE60021570T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99110865 1999-06-07
EP99110865 1999-06-07
PCT/EP2000/004958 WO2000074654A1 (en) 1999-06-07 2000-05-31 Novel preparation and administration form comprising an acid-labile active compound

Publications (2)

Publication Number Publication Date
DE60021570D1 true DE60021570D1 (de) 2005-09-01
DE60021570T2 DE60021570T2 (de) 2006-05-24

Family

ID=8238296

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60021570T Expired - Lifetime DE60021570T2 (de) 1999-06-07 2000-05-31 Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor

Country Status (31)

Country Link
US (3) US7794752B1 (de)
EP (2) EP1616562A1 (de)
JP (1) JP4980527B2 (de)
KR (1) KR100833633B1 (de)
CN (1) CN1361683A (de)
AT (1) ATE300285T1 (de)
AU (1) AU775995B2 (de)
BG (1) BG106165A (de)
BR (1) BR0011347A (de)
CA (1) CA2376202C (de)
CZ (1) CZ20014405A3 (de)
DE (1) DE60021570T2 (de)
DK (1) DK1187601T3 (de)
EA (2) EA006899B1 (de)
EE (1) EE200100660A (de)
ES (1) ES2246238T3 (de)
HK (1) HK1046643A1 (de)
HR (1) HRP20020006A2 (de)
HU (1) HUP0201637A3 (de)
IL (2) IL146504A0 (de)
MX (1) MXPA01012659A (de)
NO (1) NO20015980L (de)
PL (1) PL352882A1 (de)
PT (1) PT1187601E (de)
SI (1) SI1187601T1 (de)
SK (1) SK285247B6 (de)
TR (1) TR200103527T2 (de)
UA (1) UA74339C2 (de)
WO (1) WO2000074654A1 (de)
YU (1) YU86001A (de)
ZA (1) ZA200110000B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
US7988999B2 (en) 2000-12-07 2011-08-02 Nycomed Gmbh Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
DK1341528T3 (da) * 2000-12-07 2012-03-26 Nycomed Gmbh Hurtigtopløsende tablet omfattende en syrelabil aktiv bestanddel
BR0115989A (pt) * 2000-12-07 2004-01-13 Altana Pharma Ag Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido
JP4310605B2 (ja) * 2001-05-25 2009-08-12 大塚製薬株式会社 医薬用組成物
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20040005362A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of acid labile drugs
MXPA04008070A (es) 2003-03-10 2004-11-26 Altana Pharma Ag Novedoso proceso para la preparacion de roflumilasto.
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
WO2005074898A2 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Composition comprising (s) pantoprazole and an antibiotic for treating helicobacter pylori
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
JP5383183B2 (ja) 2005-03-16 2014-01-08 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング ロフルミラストを含有する矯味された剤形
EP1937642B1 (de) 2005-10-19 2014-09-10 Teva Pharmaceutical Industries Ltd Kristalle von laquinimod-natrium und verfahren zu deren herstellung
WO2007146248A2 (en) 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US20090318403A1 (en) * 2006-08-03 2009-12-24 Prosensa Technologies B.V. Antibiotic composition
CN101516334B (zh) 2006-09-26 2013-07-10 塔罗制药北美有限公司 用于抗生素的稳定组合物以及应用方法
ES2600920T3 (es) 2007-12-20 2017-02-13 Teva Pharmaceutical Industries, Ltd. Preparaciones estables de laquinimod
KR101094231B1 (ko) 2008-02-18 2011-12-14 하나제약 주식회사 서방성 고형 제제 및 그의 제조방법
CA2719246A1 (en) * 2008-03-26 2009-10-01 Taro Pharmaceuticals North America, Inc. Stabilizing lipid compositions for oral pharmaceutical agents
WO2010018593A2 (en) * 2008-07-03 2010-02-18 Torrent Pharmaceuticals Ltd. Gastric acid resistant benzimidazole multiple unit tablet composition
AU2009288108B2 (en) 2008-09-03 2013-10-17 Teva Pharmaceutical Industries, Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
KR101107609B1 (ko) * 2009-09-21 2012-01-25 주식회사 한양비이에스티교육 태양에너지 발전 및 응용 교육을 위한 보트형 학습교재
EP2338477A1 (de) 2009-12-15 2011-06-29 bene-Arzneimittel GmbH Zäpfchen mit Pantoprazol
US8580819B2 (en) 2010-07-09 2013-11-12 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
WO2012171540A1 (en) 2011-06-15 2012-12-20 Bene-Arzneimittel Gmbh Suppository comprising pantoprazole comprised in pellets with a cellulose core
AR090073A1 (es) 2012-02-16 2014-10-15 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
EP2916915A4 (de) 2012-11-07 2016-06-22 Teva Pharma Aminsalze von laquinimod
AU2014350208B2 (en) * 2013-11-13 2017-09-07 Tillotts Pharma Ag Multi-particulate drug delivery system
CN107412171B (zh) * 2017-04-21 2020-04-17 湖南赛隆药业有限公司 注射用左旋泮托拉唑钠长效微球冻干制剂及其制备方法
CN107007561B (zh) * 2017-04-21 2019-12-03 湖南赛隆药业有限公司 一种左旋泮托拉唑钠缓释微球及其制备方法
WO2019161175A1 (en) 2018-02-15 2019-08-22 Boston Scientific Scimed, Inc. Introducer with expandable capabilities
JP2022522114A (ja) * 2019-02-21 2022-04-14 クロマデックス，インコーポレイテッド ニコチンアミドリボシド、ニコチン酸リボシド、還元ニコチニルリボシド化合物、及びニコチニルリボシド化合物誘導体の製剤への使用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE27C (de) * 1877-08-02 GRAHL und HÖHL zu Dresden Akkumulator zum Betriebe von Hutpressen
US3065142A (en) * 1958-07-30 1962-11-20 Armour Pharma Gastric resistant medicinal preparation
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
DE2725924C3 (de) * 1977-06-08 1980-11-06 Hobeg Hochtemperaturreaktor-Brennelement Gmbh, 6450 Hanau Verfahren zur Herstellung kugelförmiger Teilchen aus niedrigschmelzenden organischen Substanzen
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
NO152588C (no) 1979-12-19 1985-10-23 Goudsche Machinefabriek Bv Kontinuerlig arbeidende krystallisator.
JPS58116471A (ja) 1981-12-29 1983-07-11 Nippon Kayaku Co Ltd ４−ヒドロキシメチル−１−フタラゾンエステル誘導体およびその塩
US4637966A (en) * 1983-10-21 1987-01-20 Gates Energy Products, Inc. Sealed lead-acid cell
US4876094A (en) * 1984-01-13 1989-10-24 Battelle Development Corporation Controlled release liquid dosage formulation
JPS60248618A (ja) * 1984-05-24 1985-12-09 Nippon Zoki Pharmaceut Co Ltd ジペプチドを含有する潰瘍治療剤
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
JO1406B1 (en) 1984-11-02 1986-11-30 سميث كلاين اند فرينش لابوراتوريز ليمتد Chemical compounds
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
EP0234485B1 (de) 1986-02-20 1992-04-01 Hoechst Aktiengesellschaft Substituierte Thienoimidazol-Derivate, Verfahren zu ihrer Herstellung, sie enthaltende pharmazeutische Zubereitungen und ihre Verwendung als Magensäuresekretionshemmer
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
CA1256109A (en) 1986-09-10 1989-06-20 Franz Rovenszky Process for the preparation of derivatives of 4, 5-dihydrooxazoles
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0768125B2 (ja) 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
JP2681373B2 (ja) 1988-07-18 1997-11-26 塩野義製薬株式会社 徐放性製剤の製造法
EP0434999B1 (de) 1989-11-29 1994-08-17 Toa Eiyo Ltd. Cycloheptenopyridinderivate, Verfahren zu ihrer Herstellung und diese enthaltende Antiulkusmitteln
FR2657257B1 (fr) * 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
US5213810A (en) * 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
DE4018642C2 (de) 1990-06-11 1993-11-25 Byk Gulden Lomberg Chem Fab Neue Salzform des 5-Difluormethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl]-1H-benzimitazol-Natriumsalzes
DE4022648C2 (de) 1990-07-17 1994-01-27 Nukem Gmbh Verfahren und Vorrichtung zur Herstellung von kugelförmigen Teilchen aus flüssiger Phase
TW209174B (de) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
KR0141909B1 (ko) * 1991-11-08 1998-06-15 보조 다꾸로 액정 표시 디바이스 제조 방법
JP2973751B2 (ja) * 1991-12-04 1999-11-08 大正製薬株式会社 矯味経口組成物の製造方法
TW272942B (de) * 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
FR2707184B1 (fr) * 1993-07-08 1995-08-11 Rhone Poulenc Nutrition Animal Procédé de préparation de sphérules contenant un principe actif alimentaire ou pharmaceutique.
EP0995447A1 (de) * 1993-09-09 2000-04-26 Takeda Chemical Industries, Ltd. Formulierung enthaltend einen Antibakteriellen und einen Antiulcus Wirkstoff
NL9400618A (nl) 1994-04-18 1995-12-01 Goudsche Machinefabriek Bv Inrichting voor het koelen en verwerken van een gesmolten produkt tot een granulaatprodukt.
CZ289804B6 (cs) 1994-07-08 2002-04-17 Astrazeneca Ab Multijednotková tabletovaná dávková forma I
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
FR2754177B1 (fr) 1996-10-07 1999-08-06 Sanofi Sa Microspheres pharmaceutiques d'acide valproique pour administration orale
WO1998020858A1 (en) * 1996-11-12 1998-05-22 Pharmacia & Upjohn Ab COMPACT MEMBER COMPRISING A PLURALITY OF POROUS CELLULOSE MATRICES, (PCMs), METHOD OF MANUFACTURING AND USE THEREOF
GB9710800D0 (en) 1997-05-23 1997-07-23 Cipla Limited Pharmaceutical composition and method of preparing it
ID20812A (id) * 1997-07-09 1999-03-11 Takeda Chemical Industries Ltd Senyawa polyol, produk dan penggunaannya
AU8699298A (en) * 1997-08-11 1999-03-01 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
AU751066B2 (en) * 1997-12-08 2002-08-08 Nycomed Gmbh Novel administration form comprising an acid-labile active compound
NL1007904C2 (nl) 1997-12-24 1999-06-25 Goudsche Machinefabriek Bv Werkwijze en inrichting voor het vormen van granulaat uit een smelt van chemische producten.
CN1293576A (zh) * 1998-03-20 2001-05-02 兴和株式会社 胃和/或十二指肠粘附性药物组合物
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
JP4370429B2 (ja) 1998-09-10 2009-11-25 東和薬品株式会社 徐放性マイクロスフエアの製造法
DE19848849A1 (de) 1998-10-22 2000-04-27 Knoll Ag Verfahren zur Herstellung von festen, sphärischen Formen, enthaltend eine biologisch aktive Substanz

Also Published As

Publication number Publication date
SK285247B6 (sk) 2006-09-07
ATE300285T1 (de) 2005-08-15
EE200100660A (et) 2003-04-15
IL146504A (en) 2007-02-11
EA200401241A1 (ru) 2005-02-24
AU5074100A (en) 2000-12-28
KR100833633B1 (ko) 2008-05-30
NO20015980D0 (no) 2001-12-06
DK1187601T3 (da) 2005-11-21
EP1616562A1 (de) 2006-01-18
WO2000074654A1 (en) 2000-12-14
HK1046643A1 (zh) 2003-01-24
JP2003501377A (ja) 2003-01-14
EP1187601A1 (de) 2002-03-20
NO20015980L (no) 2002-01-23
SI1187601T1 (sl) 2005-12-31
HUP0201637A2 (hu) 2002-11-28
HUP0201637A3 (en) 2004-05-28
BR0011347A (pt) 2002-03-19
YU86001A (sh) 2004-07-15
CN1361683A (zh) 2002-07-31
KR20020011997A (ko) 2002-02-09
CA2376202A1 (en) 2000-12-14
EP1187601B1 (de) 2005-07-27
US7794752B1 (en) 2010-09-14
US7785630B2 (en) 2010-08-31
IL146504A0 (en) 2002-07-25
EA200101266A1 (ru) 2002-06-27
CZ20014405A3 (cs) 2002-04-17
DE60021570T2 (de) 2006-05-24
PL352882A1 (en) 2003-09-22
SK18022001A3 (sk) 2002-04-04
ES2246238T3 (es) 2006-02-16
EA005803B1 (ru) 2005-06-30
ZA200110000B (en) 2002-12-24
AU775995B2 (en) 2004-08-19
TR200103527T2 (tr) 2002-04-22
UA74339C2 (uk) 2005-12-15
US7790198B2 (en) 2010-09-07
US20080069882A1 (en) 2008-03-20
CA2376202C (en) 2008-11-18
JP4980527B2 (ja) 2012-07-18
EA006899B1 (ru) 2006-04-28
PT1187601E (pt) 2005-11-30
US20060127477A1 (en) 2006-06-15
BG106165A (bg) 2002-09-30
MXPA01012659A (es) 2003-09-04
HRP20020006A2 (en) 2003-04-30

Similar Documents

Publication Publication Date Title
DE60021570D1 (de) Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor
DE60041976D1 (de) Phenoxycarbonsäureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
CO4290417A1 (es) Nuevas benzoilguanidinas como medicamentos y su preparacion .
GT200000183A (es) Aminoacidos biciclicos como agentes farmaceuticos.
NO960949L (no) Tablettert flerdoseenhetsform inneholdende protonpumpeinhibitor
PT100234A (pt) Novos esteres de alcoois aminados biciclicos e triciclicos, processo para a sua preparacao
BR0111667A (pt) Novos compostos
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
DE60134245D1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
BR0108678A (pt) Novos compostos
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
MX9202328A (es) Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo.
MY138975A (en) Novel preparation and administration form comprising an acid-labile active compound
FI964285A (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
ATE84045T1 (de) Hemmungsstoffe enkephalinase-b deren herstellung und deren pharmazeutische zusammensetzungen.
GT199800196A (es) Combinaciones de estatina-eter carboxialquilico.
GEP19991872B (en) Novel Taxoids, Preparations Thereof, and Pharmaceutical Compositions Containing Same
ATE400256T1 (de) Pharmazeutische zusammensetzung mit einem kationischen hilfsmittel
DE68906572D1 (de) Peptide mit inhibitorischer wirkung auf enzymatische systeme, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
SE9902742D0 (sv) New pharmaceutical formultion
AR026451A1 (es) Compuestos heterociclicos sililados
DE3850044D1 (de) Azelastin-Embonat, Verfahren zu seiner Herstellung und pharmazeutische Zubereitungen, die als Wirkstoff Azelastin-Embonat enthalten.
IT1204778B (it) Formulazioni farmaceutiche iniettabili di principi attivi ad attivita' anestetica generale
DE68909451D1 (de) Peptide mit inhibitorischer wirkung auf enzymatische systeme, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
HUP0204150A2 (hu) A cisz-lítium-4-ciano-4-[3-(ciklopentil-oxi)-4-metoxi-fenil]-ciklohexánkarboxilát monohidrátja, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmény

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NYCOMED GMBH, 78467 KONSTANZ, DE